Sentences with phrase «with advanced solid tumors»

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

The Maharaj Institute has an FDA IND clinical trial protocol (08001 - BMSCTI) for investigating a novel cancer therapy using transfusions of white blood cells from healthy donors to patient with advanced solid tumors.

Data from a phase II study of cabozantinib (XL184) in patients with advanced solid tumors show that the drug has activity in both bone and soft tissue.

Of the 22 patients whose tumors successfully grafted, six died before data from the mice were available, but in 13 of the remaining 16 cases, there was a positive correlation between mouse and human results.2 In a second study, performed in collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid tumors who were treated based on results from personalized PDX mice had partial tumor remissions, even in cases where genetic sequencing of the tumor showed no actionable mutations.3

Phase I Clinical Trial of VX - 970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

A phase I clinical trial conducted by investigators at the University of Texas San Antonio, showed that the combination of HCQ and the chemotherapy drug vorinostat in 27 patients with advanced solid tumors, including renal cell carcinoma and colon cancer, was clinically safe and inhibited autophagy.

Trial # 2: Phase I trial of HCQ with dose - intense temozolomide in patients with advanced solid tumors and melanoma

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

Not exact matches

«We look forward to conducting further research through the STARTRK - 2 phase II trial and are hopeful that treatment with entrectinib in patients with a range of advanced or metastatic solid tumors harboring NTRK1 / 2/3, ROS1, or ALK gene fusions will result in very meaningful benefit.»

Dent is collaborating with Massey clinical researchers to propose a study investigating the effectiveness of the combination of neratinib, sorafenib and pemetrexed in all advanced solid tumors.

Another key finding was observing the inhibitor effect on tumor models with a gene PTEN deficiency as a biomarker — of huge interest because PTEN, a tumor suppressor, is known to be defective in as many as half of all advanced solid tumor cancers.

Locally advanced pancreatic cancer has the lowest survival rate of any solid tumor, with a cumulative five - year survival rate of only 4 percent for all stages of disease.

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (OLAParib COmbinations)

A Phase 1 / 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

My Pathway: An Open - Label Phase IIA Study Evaluating Trastuzumab / Pertuzumab, Erlotinib, Vemurafenib / Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

A Phase I / II Study of Pembrolizumab (MK - 3475) in Children with Advanced Melanoma or a PD - L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma